Skip to main content
Signal8

HAEMONETICS CORP (HAE)

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Haemonetics Corporation logo

Haemonetics Corporation

NYSE:HAEHealthcare
-0.12%$119.65
AH$119.65+0.00%vs close
Mkt Cap$5.44B
Float44.52M
O/S45.5M
Vol
$ Vol
RVOL
Inst Own-
SI7.7%
Earnings
Dilution
Phase Distribution
11 lead-sponsored trials·0 active·10 completed
Phase 11
Not applicable10
(11 more as collaborator)
Status Overview
Completed10
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 1
    Completed

    Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution

    SOLX (Investigational), AS-3 (Control)

    Blood Donors

    Enrollment
    170
    Start
    Apr 2014
    Primary Completion
    Dec 2014
    Completion
    Jan 2015
    NCT02145507
  • Observational
    Completed

    Thromboelastography (TEG) Reference Range Study

    -

    Coagulation

    Enrollment
    159
    Start
    Apr 2011
    Primary Completion
    Jul 2011
    Completion
    Oct 2011
    NCT01357928
  • Observational
    Terminated

    RapidTEG MA Validation

    -

    Coagulation, Platelet Function

    Enrollment
    17
    Start
    Jul 2011
    Primary Completion
    Oct 2012
    Completion
    Oct 2012
    NCT01428102
  • Observational
    Completed

    Clinical Evaluation of the OrthoPAT Advance System

    OrthoPat Advance

    Transmission, Blood, Recipient/Donor

    Enrollment
    84
    Start
    Dec 2012
    Primary Completion
    Aug 2013
    Completion
    Aug 2013
    NCT01756976
  • Observational
    Completed

    Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)

    -

    Red Blood Cell Donation

    Enrollment
    60
    Start
    Jan 2013
    Primary Completion
    Sep 2013
    Completion
    Sep 2013
    NCT01764061
  • Observational
    Completed

    Procedure For The Reference Range Study For Absolute MA

    -

    Transmission, Blood, Recipient/Donor

    Enrollment
    161
    Start
    May 2014
    Primary Completion
    Sep 2014
    Completion
    Mar 2015
    NCT02110576
  • Not applicable
    Completed

    Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder

    POLFA (Needle Assembly), Kawasumi (Needle Assembly)

    Transmission, Blood, Recipient/Donor

    Enrollment
    62
    Start
    Jun 2015
    Primary Completion
    Jul 2015
    Completion
    Sep 2015
    NCT02476851
  • Observational
    Completed

    Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

    TEG6s DOAC Cartridge

    DOAC Eligible Subjects

    Enrollment
    385
    Start
    Aug 2016
    Primary Completion
    Sep 2017
    Completion
    Sep 2017
    NCT02798328
  • Not applicable
    Completed

    IMPACT (Improving Plasma Collection) Clinical Trial

    Updated Plasma Collection Feature, Current Plasma Collection Approach

    Apheresis Related Hypotension

    Enrollment
    3,443
    Start
    Jan 2020
    Primary Completion
    Mar 2020
    Completion
    Apr 2020
    NCT04320823
  • Observational
    Completed

    Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers

    TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen

    Healthy

    Enrollment
    181
    Start
    Jul 2021
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT06261580
  • Observational
    Completed

    An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

    TEG 6s Citrated K, KH, RTH, FFH Cartridge, Clauss Fibrinogen

    Surgery

    Enrollment
    338
    Start
    Dec 2021
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT06352125